Filing Flows › Ginkgo Bioworks Holdings (DNA) › Q3 2026 › vs Q3 2025
Ginkgo Bioworks Holdings (DNA) Q3 2026 vs Q3 2025 (year over year)
Ginkgo Bioworks Holdings's revenue fell $1.7M (-6%) from $29.4M in Q3 2025 to $27.7M in Q3 2026.
Ginkgo Bioworks Holdings, Q3 2026: revenue $27.7M (-6% year over year), operating margin -157.5%, net loss $41.0M, operating cash flow −$28.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $27.7M | $29.4M | −$1.7M | -6% |
| Other income, net | $2.4M | $1.6M | $827K | +53% |
| Income tax benefit | $271K | −$1K | $272K | — |
| Net loss | $41.0M | $80.8M | −$39.8M | -49% |
| Costs & expenses | $71.3M | $112M | −$40.3M | -36% |
| Operating costs | $71.3M | $112M | −$40.3M | -36% |
| Cost of revenue | $1.8M | $4.6M | −$2.8M | -61% |
| Research & development | $40.9M | $69.4M | −$28.4M | -41% |
| General & admin | $28.6M | $37.0M | −$8.4M | -23% |
| Operating cash sources | $48.1M | $60.3M | −$12.2M | -20% |
| Depreciation & amortization | $12.0M | $13.6M | −$1.6M | -12% |
| Share-based compensation | $7.7M | $15.0M | −$7.4M | -49% |
| Cash used in operations | $28.3M | $31.6M | −$3.3M | -10% |
| Net loss absorbed | $41.0M | $80.8M | −$39.8M | -49% |
| Working capital & other | $7.1M | −$20.5M | $27.6M | — |
Questions
How much did Ginkgo Bioworks Holdings's revenue grow year over year in Q3 2026?
Ginkgo Bioworks Holdings's revenue fell $1.7M (-6%) from $29.4M in Q3 2025 to $27.7M in Q3 2026.